个人中心 - 老虎社区

施勇兵

IP属地：浙江

帖子 · 1帖子 · 1
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 施勇兵施勇兵
  ·2021-07-12
  资金量的散户没什么优势可言
  腾盛博药-B一手中签率5%，认购40手稳中一手
  7月12日，腾盛博药-B发布公告，发售价厘定为每股发售股份22.25港元，全球发售所得款项净额预计约为23.34亿港元(假设超额配股权未获行使)，预期股份将于2021年7月13日(星期二)上午九时正(
  腾盛博药-B一手中签率5%，认购40手稳中一手
  2,465 1
  3
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4087643261935500","uuid":"4087643261935500","gmtCreate":1624592230105,"gmtModify":1624592230105,"name":"施勇兵","pinyin":"sybshiyongbing","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":8,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":146344643,"gmtCreate":1626055710782,"gmtModify":1626057504947,"author":{"id":"4087643261935500","authorId":"4087643261935500","name":"施勇兵","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087643261935500","authorIdStr":"4087643261935500"},"themes":[],"htmlText":"资金量的散户没什么优势可言","listText":"资金量的散户没什么优势可言","text":"资金量的散户没什么优势可言","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/146344643","repostId":"1128521631","repostType":2,"repost":{"id":"1128521631","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626047703,"share":"https://ttm.financial/m/news/1128521631?lang=&edition=full","pubTime":"2021-07-12 07:55","market":"hk","language":"zh","title":"腾盛博药-B一手中签率5%，认购40手稳中一手","url":"https://stock-news.laohu8.com/highlight/detail?id=1128521631","media":"老虎资讯综合","summary":"7月12日，腾盛博药-B发布公告，发售价厘定为每股发售股份22.25港元，全球发售所得款项净额预计约为23.34亿港元(假设超额配股权未获行使)，预期股份将于2021年7月13日(星期二)上午九时正(","content":"<p>7月12日，<a href=\"https://laohu8.com/S/02137\">腾盛博药-B</a>发布公告，发售价厘定为每股发售股份22.25港元，全球发售所得款项净额预计约为23.34亿港元(假设超额配股权未获行使)，预期股份将于2021年7月13日(星期二)上午九时正(香港时间)开始在联交所买卖。</p>\n<p><b>老虎资讯整理相关数据如下：</b></p>\n<p><img src=\"https://static.tigerbbs.com/6804fe5ca9085f6481244e4a826c03d7\" tg-width=\"1059\" tg-height=\"824\" referrerpolicy=\"no-referrer\"></p>\n<p><b>分配结果：</b></p>\n<p>甲组每手500股，一手中签率5%，认购40手稳中一手。</p>\n<p>乙组头为3万股（600手），获配4500股（9手）。</p>\n<p><img src=\"https://static.tigerbbs.com/6cc9c803bdb4af0ada0033deaba2cc37\" tg-width=\"726\" tg-height=\"769\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/8be19769443a8c996cbf0f219b3cd790\" tg-width=\"734\" tg-height=\"392\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/6f25a813ef2012066cd493f9512952f7\" tg-width=\"738\" tg-height=\"481\" referrerpolicy=\"no-referrer\"></p>\n<p>倘超额配股权获悉数行使，公司将就超额配股权获行使后拟发行的1673.7万股额外发售股份收取额外所得款项净额约3.57亿港元。</p>\n<p>香港公开发售获大量超额认购。合共接获24.65万份有效申请，认购合共32.59亿股香港发售股份，相当于香港公开发售项下初步可供认购香港发售股份总数1115.8万股的约292倍。</p>\n<p>由于香港公开发售的超额认购超过100倍，4463.2万股发售股份已由国际发售重新分配至香港公开发售。香港公开发售项下发售股份的最终数目由此增加至5579万股发售股份，相当于全球发售项下初步可供认购发售股份总数的50%(于任何超额配股权获行使前)。</p>\n<p>国际发售项下初步提呈发售的发售股份已获大幅超额认购，相当于国际发售项下初步可供认购发售股份总数的约12倍。于将发售股份由国际发售重新分配至香港公开发售后，国际发售项下发售股份最终数目为5579万股，相当于全球发售项下初步可供认购发售股份总数的50%(于任何超额配股权获行使前)。国际发售项下超额分配1673.7万股发售股份，并共有160名承配人。</p>\n<p>基于发售价每股发售股份22.25港元，根据基石投资协议，基石投资者已认购合共5302.75万股发售股份，相当于紧随全球发售完成后本公司已发行股本的约7.51%及全球发售项下发售股份数目的47.52%，两种情况均假设超额配股权未获行使。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>腾盛博药-B一手中签率5%，认购40手稳中一手</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n腾盛博药-B一手中签率5%，认购40手稳中一手\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-07-12 07:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>7月12日，<a href=\"https://laohu8.com/S/02137\">腾盛博药-B</a>发布公告，发售价厘定为每股发售股份22.25港元，全球发售所得款项净额预计约为23.34亿港元(假设超额配股权未获行使)，预期股份将于2021年7月13日(星期二)上午九时正(香港时间)开始在联交所买卖。</p>\n<p><b>老虎资讯整理相关数据如下：</b></p>\n<p><img src=\"https://static.tigerbbs.com/6804fe5ca9085f6481244e4a826c03d7\" tg-width=\"1059\" tg-height=\"824\" referrerpolicy=\"no-referrer\"></p>\n<p><b>分配结果：</b></p>\n<p>甲组每手500股，一手中签率5%，认购40手稳中一手。</p>\n<p>乙组头为3万股（600手），获配4500股（9手）。</p>\n<p><img src=\"https://static.tigerbbs.com/6cc9c803bdb4af0ada0033deaba2cc37\" tg-width=\"726\" tg-height=\"769\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/8be19769443a8c996cbf0f219b3cd790\" tg-width=\"734\" tg-height=\"392\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/6f25a813ef2012066cd493f9512952f7\" tg-width=\"738\" tg-height=\"481\" referrerpolicy=\"no-referrer\"></p>\n<p>倘超额配股权获悉数行使，公司将就超额配股权获行使后拟发行的1673.7万股额外发售股份收取额外所得款项净额约3.57亿港元。</p>\n<p>香港公开发售获大量超额认购。合共接获24.65万份有效申请，认购合共32.59亿股香港发售股份，相当于香港公开发售项下初步可供认购香港发售股份总数1115.8万股的约292倍。</p>\n<p>由于香港公开发售的超额认购超过100倍，4463.2万股发售股份已由国际发售重新分配至香港公开发售。香港公开发售项下发售股份的最终数目由此增加至5579万股发售股份，相当于全球发售项下初步可供认购发售股份总数的50%(于任何超额配股权获行使前)。</p>\n<p>国际发售项下初步提呈发售的发售股份已获大幅超额认购，相当于国际发售项下初步可供认购发售股份总数的约12倍。于将发售股份由国际发售重新分配至香港公开发售后，国际发售项下发售股份最终数目为5579万股，相当于全球发售项下初步可供认购发售股份总数的50%(于任何超额配股权获行使前)。国际发售项下超额分配1673.7万股发售股份，并共有160名承配人。</p>\n<p>基于发售价每股发售股份22.25港元，根据基石投资协议，基石投资者已认购合共5302.75万股发售股份，相当于紧随全球发售完成后本公司已发行股本的约7.51%及全球发售项下发售股份数目的47.52%，两种情况均假设超额配股权未获行使。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128521631","content_text":"7月12日，腾盛博药-B发布公告，发售价厘定为每股发售股份22.25港元，全球发售所得款项净额预计约为23.34亿港元(假设超额配股权未获行使)，预期股份将于2021年7月13日(星期二)上午九时正(香港时间)开始在联交所买卖。\n老虎资讯整理相关数据如下：\n\n分配结果：\n甲组每手500股，一手中签率5%，认购40手稳中一手。\n乙组头为3万股（600手），获配4500股（9手）。\n\n倘超额配股权获悉数行使，公司将就超额配股权获行使后拟发行的1673.7万股额外发售股份收取额外所得款项净额约3.57亿港元。\n香港公开发售获大量超额认购。合共接获24.65万份有效申请，认购合共32.59亿股香港发售股份，相当于香港公开发售项下初步可供认购香港发售股份总数1115.8万股的约292倍。\n由于香港公开发售的超额认购超过100倍，4463.2万股发售股份已由国际发售重新分配至香港公开发售。香港公开发售项下发售股份的最终数目由此增加至5579万股发售股份，相当于全球发售项下初步可供认购发售股份总数的50%(于任何超额配股权获行使前)。\n国际发售项下初步提呈发售的发售股份已获大幅超额认购，相当于国际发售项下初步可供认购发售股份总数的约12倍。于将发售股份由国际发售重新分配至香港公开发售后，国际发售项下发售股份最终数目为5579万股，相当于全球发售项下初步可供认购发售股份总数的50%(于任何超额配股权获行使前)。国际发售项下超额分配1673.7万股发售股份，并共有160名承配人。\n基于发售价每股发售股份22.25港元，根据基石投资协议，基石投资者已认购合共5302.75万股发售股份，相当于紧随全球发售完成后本公司已发行股本的约7.51%及全球发售项下发售股份数目的47.52%，两种情况均假设超额配股权未获行使。","news_type":1,"symbols_score_info":{"02137":0.9}},"isVote":1,"tweetType":1,"viewCount":2465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}